Literature DB >> 26330926

Significance of the Extracapsular Spread of Metastatic Lymph Nodes in Papillary Thyroid Carcinoma.

Chang Ho Park1, Chang Myeon Song1, Yong Bae Ji1, Ju Yeon Pyo2, Ki Jong Yi2, Young Soo Song2, Yong Wook Park2, Kyung Tae1.   

Abstract

OBJECTIVES: The extracapsular spread (ECS) of metastatic lymph nodes is associated with aggressive tumor behavior, and is regarded as a major risk factor for local recurrence in patients with head and neck squamous cell carcinoma. However, the significance of ECS of metastatic lymph nodes has not been well established in well-differentiated thyroid carcinoma. The purpose of this study was to examine this question.
METHODS: A retrospective review was performed of 335 patients with papillary thyroid carcinoma who underwent total thyroidectomy with lymph node dissection from April 2001 to December 2009. We analyzed various clinical characteristics, pathologic factors, and the size, number, and ECS of foci in metastatic lymph nodes.
RESULTS: On pathologic review, 201 of the patients (56.6%) had lymph node metastasis. This was significantly related to age and tumor size. ECS was noted in 64 of these 201 patients (31.8%), and was significantly related to male gender, tumor size, presence of extrathyroidal extension, metastatic lymph node size, and focus size. Recurrence occurred in 13 patients (3.9%), and the presence of ECS was significantly related to recurrence.
CONCLUSION: ECS of metastatic lymph nodes is an important prognostic factor for loco-regional recurrence in papillary thyroid carcinoma.

Entities:  

Keywords:  Extracapsular Spread; Metastatic Lymph Node; Thyroid Cancer, Papillary

Year:  2015        PMID: 26330926      PMCID: PMC4553362          DOI: 10.3342/ceo.2015.8.3.289

Source DB:  PubMed          Journal:  Clin Exp Otorhinolaryngol        ISSN: 1976-8710            Impact factor:   3.372


INTRODUCTION

Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid. It has a good prognosis due to its slow growth and less invasive behavior [1]. However, lymph node (LN) metastasis or aggressive behavior, such as local invasion and distant metastasis are seen in some cases of PTC. Cervical LN metastasis is common in PTC; it is associated with recurrence and is a prognostic factor in older patients [23]. Microscopic examination of metastatic LNs can establish whether tumor foci are located within LNs with intact nodal capsules, or extend in to the surrounding perinodal fat tissue beyond the fibrous capsules of the LNs. In patients with head and neck squamous cell carcinoma, extracapsular spread (ECS) is associated with aggressive tumor behavior, and is regarded as a major risk factor for local recurrence [45]. However, in well-differentiated thyroid carcinoma, the significance of ECS has not been well established. We hypothesized that ECS of metastatic LN may affect the prognosis of PTC. The purpose of this study was therefore to determine the clinical significance of ECS of metastatic LN in PTC.

MATERIALS AND METHODS

We retrospectively reviewed the data of 722 patients who underwent thyroidectomy for the treatment of PTC from April 2001 to November 2009. We confined this study to patients who underwent total thyroidectomy and LN dissection including central or lateral neck dissection. We excluded patients who did not receive neck dissection or total thyroidectomy, and had distant metastasis before operation, as well as recurrent cases. Finally, 335 patients were enrolled. The study was approved by the Institutional Review Board of Hanyang University Hospital (HYUH 2013-12-008-003). Preoperative imaging was performed by neck ultrasonography (US) and computed tomography (CT), and in some cases, fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG-PET/CT). We analyzed various clinicopathologic characteristics, the size and number of metastatic foci, and ECS in metastatic LNs. Pathologic review was undertaken by two expert pathologists in our institution. Tumor size was defined by the length of the long axis of the largest nodule, and ECS by the existence of tumor foci that extended into the perinodal fat tissue surrounding the fibrous capsule of the LN (Fig. 1). Positive ECS patients were those who had ECS of one or more LNs.
Fig. 1

Pathologic findings of lymph node metastasis in papillary thyroid carcinoma (H&E, ×40). (A) Metastatic tumor foci with intact lymph node capsule. (B) Metastatic tumor foci extend to the surrounding perinodal fat tissue beyond the fibrous capsule of the lymph node.

Clinically positive LN was defined as LN detected by palpation or preoperative image study such as US, CT, or 18FDG-PET/CT. We did not perform prophylactic neck dissection in the lateral compartment. We only performed therapeutic lateral compartment neck dissection when LN metastasis was suspicious clinically or LN metastasis was confirmed by US-guided fine needle aspiration cytology. Tumors were classified according to 7th edition of the American Joint Committee on Cancer (AJCC) Staging System [6]. Local recurrence was evaluated every 6-12 months by neck US, radioactive iodine scan and stimulated serum thyroglobulin levels. Statistical analysis was performed using IBM SPSS ver. 21.0 (IBM Co., Armonk, NY, USA). Pearson chi-square test, Fisher exact test, or the independent t-test was used in evaluating the relation between local recurrence and various clinical factors, as well as between ECS and various clinical factors. After identifying significant clinical factors, a multiple regression analysis was performed to identify risk factors related to local recurrence and ECS.

RESULTS

The mean age of the 335 patients was 46.9 (standard deviation, ±13.1) years, and 80.6% were female. Pathologic cervical LN metastasis was found in 201 patients (56.6%). According to the AJCC staging system, the numbers of patients in stages I, II, III, and IV were 185 (55.2%), 9 (2.7%), 101 (30.1%), and 40 (11.7%), respectively. Postoperative radioactive iodine ablation was performed in 306 patients (91.3%), and the mean follow-up period was 69.0 months (range, 33 to 147 months). Factors related to LN metastasis are listed in Table 1. Cervical LN metastasis was related to age, gender, and tumor size (P=0.008, P=0.030, and P<0.001, respectively).
Table 1

Factors related to cervical lymph nodes metastasis in papillary thyroid carcinoma

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

Of 201 patients with cervical LN metastasis, the proportions of LNs that were detected by preoperative physical examination or imaging were 13.7% (20/146) and 100% (55/55) in central and lateral compartment, respectively. A comparison between the clinically positive and the clinically negative LN groups is shown in Table 2. Metastatic LN detected clinically was related to metastatic LN size (P=0.001).
Table 2

Factors related to clinically detected lymph node metastasis

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

Pathologic review of the 201 patients with cervical LN metastasis showed that 64 (31.8%) had ECS. Positive ECS was significantly related to male gender, tumor size, and extrathyroidal extension (ETE) (Table 3).
Table 3

Factors related to extracapsular spread (ECS) of metastatic lymph nodes in papillary thyroid carcinoma

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

ECS was found in 242 of the total of 1,121 LNs (21.6%) removed in all patients. It was seen in 11.0% (49/445) and 28.6% (193/676) of the LNs in the central and lateral LN metastasis groups, respectively. The relationship between ECS and nodal characteristics is detailed in Table 4. Larger metastatic LN size and focus size were independent risk factors for ECS in multivariate regression analysis (P<0.001, each).
Table 4

Factors related with to spread in metastatic lymph nodes

Values are presented as mean±standard deviation or number (%).

ECS, extracapsular spread; LN, lymph node.

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

Recurrence in cervical LNs occurred in 13 patients (3.9%); two in the group without LN metastasis and eleven in the group with positive LN metastasis. There was no recurrence in the thyroid bed or other organs. Gender, tumor size, multiplicity, bilaterality, central LN metastasis, metastatic LN size, and metastatic foci size were not significantly related to loco-regional recurrence. On the other hand, lower age, presence of ETE, lateral LN metastasis, and ECS were risk factors for loco-regional recurrence in multivariate regression analysis (Table 5). In a subgroup analysis of the cases with cervical LN metastasis, loco-regional recurrence was significantly associated with age and presence of ECS (Table 6). Radioactive iodine ablation did not significantly influence local recurrence (P=0.394).
Table 5

Factors related to loco-regional recurrence in papillary thyroid carcinoma

Values are presented as mean±standard deviation or number (%).

CCLN, central compartment lymph node; LCLN, lateral compartment lymph node; LN, lymph node.

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

Table 6

Factors related to loco-regional recurrence in papillary thyroid carcinoma with lymph node metastasis

Values are presented as mean±standard deviation or number (%).

*Student t-test. †Chi-square test. ‡Multiple regression analysis.

In the group of patients who underwent only central neck dissection, the site of LN recurrence was the central compartment in one case, the lateral compartment in five cases, and both central and lateral compartment in one case. In the group who underwent lateral neck dissection, the site of LN recurrence was the central compartment in two cases and the lateral compartment in the other four.

DISCUSSION

Rates of cervical LN metastasis in PTC vary. The frequency of cervical LN metastasis was reported to be 20%-41% as detected clinically by preoperative physical examination, US or CT, whereas pathologically confirmed cervical LN metastasis occurred in 20%-80% of cases [78910]. In this study, 22.4% of the patients (75/335) had clinically detectable LN metastasis by physical examination or imaging study while 60.0% (201/335) had LN metastasis confirmed pathologically after surgery. According to several studies, cervical LN metastasis is related to lower age, large tumor size, presence of ETE, and positive BRAF V600E mutation [111213]. In this study, lower age, male gender, and large tumor size were associated with increased cervical LN metastasis. Cervical LN metastasis in differentiated thyroid carcinoma has no definite effect on prognosis, but is a critical factor for local recurrence [14]. In this study, young age, ETE, lateral LN metastasis, and ECS of metastatic LNs were significantly related to loco-regional recurrence. The size and number of metastatic LNs is thought to be associated with local recurrence although this is controversial [111516]. In this study, the size of metastatic LNs was not significantly correlated with loco-regional recurrence. Several studies have concluded that ECS of metastatic LNs is related to lower age, large tumor size, presence of ETE, and size and number of metastatic LNs [11121718192021]. T4 tumors and high-risk features according to the American Thyroid Association guidelines were associated with ECS of metastatic LNs [19]. In this study, ECS of metastatic LNs was related to male gender, large tumor size, presence of ETE, large size of metastatic LNs and large size of metastatic foci. ECS of metastatic LNs is regarded as a poor prognostic factor for local recurrence and survival in some human cancers such as head and neck, breast and bladder cancers. ECS of metastatic LNs, especially in head and neck cancers, is considered an important adverse prognostic factor for local recurrence and distant metastasis, as well as for survival [45]. There are differing opinions about the significance of ECS in PTC. Several studies have reported it to be a prognostic indicator for local recurrence, distant metastasis, and decreased survival [11121718192021]. A recent paper concluded that the risk of recurrence was 1% in patients with LN metastasis without ECS, 4% in those with three metastatic LNs showing ECS, and 32% in those with more than three metastatic LNs showing ECS [11]. According to another study more than three metastatic LNs showing ECS was also a significant risk factor for persistent disease and recurrent disease [20]. In addition, concurrent BRAF V600E mutation and ECS of metastatic LNs have been shown to predict significantly worse disease free survival [18]. However, in other studies workers found that recurrence was not correlated with ECS of metastatic LNs [2223]. In our study, ECS of metastatic LNs was significantly associated with loco-regional recurrence. Young age and presence of ECS, in particular, were significantly associated with recurrence among patients with cervical LN metastasis. Therefore, close postoperative surveillance and appropriate adjuvant treatment should be considered in patients with ECS in order to detect early recurrence and minimize loco-regional recurrence. In this study, only two patients died. ECS of metastatic LNs was not correlated with survival although the follow-up period was relatively short to evaluate survival rate accurately. In conclusion, ECS of metastatic LNs in PTC is an important prognostic factor for loco-regional recurrence.
  22 in total

1.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period.

Authors:  Iwao Sugitani; Nobukatsu Kasai; Yoshihide Fujimoto; Akio Yanagisawa
Journal:  Surgery       Date:  2004-02       Impact factor: 3.982

2.  Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.

Authors:  Julio Ricarte-Filho; Ian Ganly; Michael Rivera; Nora Katabi; Weimin Fu; Ashok Shaha; R Michael Tuttle; James A Fagin; Ronald Ghossein
Journal:  Thyroid       Date:  2012-04-03       Impact factor: 6.568

3.  Reevaluating the prognostic significance of age in differentiated thyroid cancer.

Authors:  Samuel L Oyer; Valerie A Smith; Eric J Lentsch
Journal:  Otolaryngol Head Neck Surg       Date:  2012-03-30       Impact factor: 3.497

4.  Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

Authors:  Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner
Journal:  World J Surg       Date:  2002-05-21       Impact factor: 3.352

5.  An evaluation of lymph node yield and lymph node ratio in well-differentiated thyroid carcinoma.

Authors:  Shannon H Beal; Steven L Chen; Philip D Schneider; Steve R Martinez
Journal:  Am Surg       Date:  2010-01       Impact factor: 0.688

6.  Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis.

Authors:  Sophie Leboulleux; Carole Rubino; Eric Baudin; Bernard Caillou; Dana M Hartl; Jean-Michel Bidart; Jean-Paul Travagli; Martin Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

7.  Inclusion of extracapsular spread in the pTNM classification system: a proposal for patients with head and neck carcinoma.

Authors:  Julia de Juan; Jacinto García; Montserrat López; César Orús; Eduard Esteller; Miquel Quer; Xavier León
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2013-05       Impact factor: 6.223

8.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

9.  Nodal status of central lymph nodes as a negative prognostic factor for papillary thyroid carcinoma.

Authors:  Yoon Se Lee; Yun-Sung Lim; Jin-Choon Lee; Soo-Geun Wang; In-Ju Kim; Seok-Man Son; Dong Hoon Shin; Byung-Joo Lee
Journal:  J Surg Oncol       Date:  2013-05-02       Impact factor: 3.454

10.  Optimal surgical extent of lateral and central neck dissection for papillary thyroid carcinoma located in one lobe with clinical lateral lymph node metastasis.

Authors:  Hyo Sub Keum; Yong Bae Ji; Jong Min Kim; Jin Hyeok Jeong; Woong Hwan Choi; You Hern Ahn; Kyung Tae
Journal:  World J Surg Oncol       Date:  2012-10-25       Impact factor: 2.754

View more
  17 in total

1.  Level I lymph node involvement in patients with N1b papillary thyroid carcinoma: a prospective study.

Authors:  Ahmad M Eweida; Mahmoud F Sakr; Yasser Hamza; Mohamed R Khalil; Essam Gabr; Tarek Koraitim; Hatem F Al-Wagih; Waleed Abo-Elwafa; Tarek Ezzat Abdel-Aziz; Ahmed A Diab; Basma El-Sabaa; Aman S Nabawi
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-20       Impact factor: 2.503

2.  Pathologic features of metastatic lymph nodes identified from prophylactic central neck dissection in patients with papillary thyroid carcinoma.

Authors:  Hyoung Shin Lee; Chanwoo Park; Sung Won Kim; Woong Jae Noh; Soo Jin Lim; Bong Kwon Chun; Beom Su Kim; Jong Chul Hong; Kang Dae Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-12       Impact factor: 2.503

3.  Preoperative application of carbon nanoparticles in bilateral axillo-breast approach robotic thyroidectomy for papillary thyroid cancer.

Authors:  Hui Ouyang; Fada Xia; Zhejia Zhang; Rong Cong; Xinying Li
Journal:  Gland Surg       Date:  2021-12

4.  Low transverse incision for lateral neck dissection in patients with papillary thyroid cancer: improved cosmesis.

Authors:  Chang Myeon Song; Yong Bae Ji; In Sik Kim; Ji Young Lee; Dong Sun Kim; Kyung Tae
Journal:  World J Surg Oncol       Date:  2017-05-04       Impact factor: 2.754

5.  Number of Metastatic Lymph Nodes and Ratio of Metastatic Lymph Nodes to Total Number of Retrieved Lymph Nodes Are Risk Factors for Recurrence in Patients With Clinically Node Negative Papillary Thyroid Carcinoma.

Authors:  Chuan-Ming Zheng; Yong Bae Ji; Chang Myeon Song; Ming-Hua Ge; Kyung Tae
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-10-17       Impact factor: 3.372

6.  Diagnostics of Thyroid Malignancy and Indications for Surgery in the Elderly and Younger Counterparts: Comparison of 3,749 Patients.

Authors:  Krzysztof Kaliszewski; Dorota Diakowska; Marta Strutyńska-Karpińska; Beata Wojtczak; Michał Aporowicz; Zdzisław Forkasiewicz; Waldemar Balcerzak; Tadeusz Łukieńczuk; Paweł Domosławski
Journal:  Biomed Res Int       Date:  2017-10-16       Impact factor: 3.411

7.  LAMB3 mediates metastatic tumor behavior in papillary thyroid cancer by regulating c-MET/Akt signals.

Authors:  Seung-Nam Jung; Hyun Sil Lim; Lihua Liu; Jae Won Chang; Young Chang Lim; Ki Sang Rha; Bon Seok Koo
Journal:  Sci Rep       Date:  2018-02-09       Impact factor: 4.379

8.  Nodal characteristics associated with adverse prognosis in oral cavity cancer are linked to host immune status.

Authors:  Cristina Valero; Daniella K Zanoni; Anjali Pillai; Bin Xu; Nora Katabi; Ronald A Ghossein; Ian Ganly; Luc G T Morris; Jatin P Shah; Richard J Wong; Snehal G Patel
Journal:  J Surg Oncol       Date:  2020-09-24       Impact factor: 3.454

9.  Postoperative Hypoparathyroidism and the Viability of the Parathyroid Glands During Thyroidectomy.

Authors:  Yong Bae Ji; Chang Myeon Song; Eui Suk Sung; Jin Hyeok Jeong; Chang Beom Lee; Kyung Tae
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-08-13       Impact factor: 3.372

10.  Accuracy of preoperative MRI to assess lateral neck metastases in papillary thyroid carcinoma.

Authors:  Suvi Renkonen; Riikka Lindén; Leif Bäck; Robert Silén; Hanna Mäenpää; Laura Tapiovaara; Katri Aro
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-09-02       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.